| Overview |
| bsm-62519r-apc-cy5 |
| CLPTM1 Recombinant Monoclonal Antibody, APC-Cy5 Conjugated |
| WB, FCM, IF(ICC) |
| Human |
| Specifications |
| APC-Cy5 |
| Rabbit |
| KLH conjugated synthetic peptide derived from human Putative lipid scramblase CLPTM1 |
| Monoclonal |
| Recombinant |
| IgG |
| Lot dependent |
| Purified by Protein A. |
| Aqueous buffered solution containing 0.01M TBS (pH7.4) with 1% BSA, 0.02% Proclin300 and 50% Glycerol. |
| Store at -20°C. Aliquot into multiple vials to avoid repeated freeze-thaw cycles. |
| Target |
| 1209 |
| O96005 |
| HS9; N14. |
| Involved in GABAergic but not glutamatergic transmission. Binds and traps GABAA receptors in the endoplasmic reticulum (ER). Modulates postsynaptic GABAergic transmission, and therefore inhibitory neurotransmission, by reducing the plasma membrane expression of these receptors. Altered GABAergic signaling is one among many causes of cleft palate. |
| Application Dilution |
| WB |
1:300-5000 |
| FCM |
1:20-100 |
| IF(ICC) |
1:50-200 |
Powered by Bioz